Sorafenib concomitantly used with TACE (Transarterial Chemoembolization) in uHCC (unresectable hepatocellular carcinoma) patients in China (SUCCESS)
This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course (concomitantly use no later than the 3rd TACE procedure) has been made under real-life practice conditions.this study will also conclude the safety and effectiveness of combination in uHCC patients.
- Patients with histologically/ cytologically documented or radiographically diagnosed unresectable HCC who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made. Radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or MRI; - Patients receive the first dose of sorafenib no later than 1 week (<=7days) after the 3rd TACE procedure - Patients did not receive other prior systemic treatment by using target therapy - Patients must sign the informed consent form; - Patients must have a life expectancy of at least 3 months; - The physician must be willing to complete and submit all CRFs; - The physician must be willing to submit to a site audit with verification of source documents and validation of data reported;
- The first dose of sorafenib 7 days after the 3nd TACE procedure - Exclusion criteria must follow the approved local product information
Many Locations, China
E-mail: [email protected]
Phone: +49 30 300139003
Study on Transarterial chemoembolization combined with Sorafenib in Chinese patients with unresectable hepatocellular carcinoma (SUCCESS)